S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

AC Immune Stock Forecast, Price & News

-0.07 (-0.91 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $7.59
50-Day Range
MA: $6.88
52-Week Range
Now: $7.59
Volume627,193 shs
Average Volume1.40 million shs
Market Capitalization$544.51 million
P/E RatioN/A
Dividend YieldN/A
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
AC Immune logo


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ACIU
Year FoundedN/A



Sales & Book Value

Annual Sales$111.75 million
Cash Flow$0.85 per share
Book Value$4.06 per share


Net Income$45.74 million
Net Margins-392.56%


Market Cap$544.51 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.31 out of 5 stars

Medical Sector

714th out of 1,960 stocks

Pharmaceutical Preparations Industry

349th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.07 (-0.91 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

Is AC Immune a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AC Immune stock.
View analyst ratings for AC Immune
or view top-rated stocks.

What stocks does MarketBeat like better than AC Immune?

Wall Street analysts have given AC Immune a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AC Immune wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for AC Immune

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings results on Wednesday, November, 18th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.01. The firm had revenue of $1.22 million for the quarter, compared to analyst estimates of $0.93 million. AC Immune had a negative net margin of 392.56% and a negative trailing twelve-month return on equity of 23.88%.
View AC Immune's earnings history

How has AC Immune's stock been impacted by COVID-19?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACIU shares have increased by 38.3% and is now trading at $7.59.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ACIU?

1 analysts have issued 12 month target prices for AC Immune's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate AC Immune's share price to reach $11.00 in the next year. This suggests a possible upside of 44.9% from the stock's current price.
View analysts' price targets for AC Immune
or view top-rated stocks among Wall Street analysts.

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 64)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 43)
  • Mr. Piergiorgio Donati, Chief Technical Operations Officer (Age 50)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 63)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 50)
  • Joshua Drumm Ph.D., Head of Investor Relations
  • Mr. Alexandre Caratsch, Gen. Counsel (Age 55)
  • Judith Moore, Global Head of Communications
  • Mr. Gautam Maitra Fil. Lic, Head of Regulatory & External Affairs and Sr. Expert
  • Dr. Maria Pihlgren Ph.D., Head of Biology

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune CEO Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among AC Immune's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.91%), Renaissance Technologies LLC (0.81%), Wells Fargo & Company MN (0.45%), Verition Fund Management LLC (0.27%), Banque Cantonale Vaudoise (0.08%) and Squarepoint Ops LLC (0.07%).

Which major investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Verition Fund Management LLC, and BlackRock Inc..

Which major investors are buying AC Immune stock?

ACIU stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Squarepoint Ops LLC, Engineers Gate Manager LP, and Banque Cantonale Vaudoise.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $7.59.

How much money does AC Immune make?

AC Immune has a market capitalization of $544.51 million and generates $111.75 million in revenue each year. The company earns $45.74 million in net income (profit) each year or $0.60 on an earnings per share basis.

How many employees does AC Immune have?

AC Immune employs 115 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is www.acimmune.com.

Where are AC Immune's headquarters?

AC Immune is headquartered at EPFL Innovation Park Building B, Lausanne V8, 1015.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.